CM-4620

CalciMedica has secured a $32.5M credit facility from Avenue Venture Opportunities Fund, with an initial $10M tranche extending cash runway into mid-2026.

Post-hoc analysis of CARDEA Phase 2 trial reveals Auxora reduced mortality by 62.7% in COVID-19 patients with acute kidney injury compared to placebo, with benefits persisting through 60 days.

Zegocractin, a CRAC channel inhibitor, significantly reduced the time to solid food tolerance in acute pancreatitis patients with systemic inflammatory response syndrome (SIRS).